Short report

DOI: 10.4244/EIJ-D-20-00170

Impact of the CABG SYNTAX score on all-cause death at 10 years: a SYNTAX Extended Survival (SYNTAXES) substudy

Kuniaki Takahashi1, MD; Daniel J.F.M. Thuijs2, MD, PhD; Hironori Hara1, MD; Rutao Wang3,4, MD; Friedrich-Wilhelm Mohr5, MD, PhD; Marie-Claude Morice6, MD, PhD; David R. Holmes Jr7, MD; Arie Pieter Kappetein2, MD, PhD; Stuart J. Head2, MD, PhD; Yoshinobu Onuma3, MD, PhD; Patrick W. Serruys3, MD, PhD

Introduction

The anatomical SYNTAX score (SS) has been considered an important tool in the quantitative assessment of the complexity of coronary artery disease (CAD) and in facilitating the risk stratification of patients undergoing revascularisation. However, the anatomical SS, obtained prior to revascularisation, has been shown not to be associated with short- and long-term clinical outcomes in patients who received coronary artery bypass grafting (CABG). These findings prompted the development of the CABG SS, assessing native residual stenotic lesions, taking into account the extent of revascularisation by bypass grafting, with the aim of helping to identify patients at higher risk of future adverse events. The primary report about the CABG SS, assessed at 15 months after surgical revascularisation in 115 patients enrolled in the SYNTAX-LE MANS substudy, demonstrated the feasibility (98.3%, n=113) and reproducibility of the score1, and evaluated clinical outcomes up to five years.

The SYNTAX Extended Survival (SYNTAXES) trial has recently reported vital status up to 10 years in patients enrolled in the original SYNTAX trial2. The aim of this study is therefore to update our previous findings concerning the impact of the CABG SS on 10-year all-cause death in patients with previous CABG.

Methods

Details of the trial design of the SYNTAX trial and the pre-specified SYNTAX-LE MANS substudy have been reported previously1 and are summarised in Supplementary Appendix 1. The methodology of the CABG SS has been reported previously1 and is described briefly in Figure 1 and Supplementary Appendix 1.

Figure 1. A representative case of the CABG SS. Coronary segment-weighting derived from the Leaman score (A), and segment-weighting multiplication factors depending on the severity of the lesion (B). These were used to calculate points for deduction from the SS. C) The SS was 44.5 points (upper panel). A patent LIMA to LAD without obstructive disease (lower right panel) resulted in the deduction of 2.5×5 points (×5 segment-weighting due to occluded native coronary artery) from the SS. A patent SVG to RCA without obstructive disease (lower left panel) resulted in deduction of 1×5 points. Thus, the CABG SS was 44.5–(12.5+5)=27 points. An arrow indicates the occluded native coronary artery. CABG: coronary artery bypass grafting; LCA: left coronary artery; LIMA: left internal mammary artery; RCA: right coronary artery; SS: SYNTAX score; SVG: saphenous vein graft

Results

Vital status at 10-year follow-up was complete in 110 (97.3%) patients. The median duration of follow-up was 11.3 years (interquartile range: 10.1-12.0) overall, 11.3 years (10.5-11.9) in the low CABG SS group, and 11.4 years (7.3-12.0) in the high CABG SS group. Baseline characteristics according to the CABG SS are summarised in Supplementary Table 1. Medication status is presented in Supplementary Table 2. Although clinical characteristics were comparable between the low and high CABG SS groups, the high CABG SS group had more complex CAD with a higher anatomical SS, resulting in a lower rate of complete revascularisation. A representative case of the CABG SS is shown in Figure 1.

The discriminative ability of the CABG SS for predicting all-cause death at 10 years and at maximum follow-up showed a c-statistic of 0.60 and 0.67, respectively (Supplementary Table 3), which suggests a possibly helpful discrimination. Cumulative incidences of all-cause death according to the CABG SS are presented in Figure 2. A higher CABG SS was associated with an increased risk of all-cause death at 10 years (27.8% vs 14.0%; hazard ratio [HR] 2.24, 95% confidence interval [CI]: 0.95-5.30; log-rank p=0.058) and at maximum follow-up (40.6% vs 14.0%; HR 3.11, 95% CI: 1.38-7.02; log-rank p=0.004) (Supplementary Table 4).

Figure 2. All-cause death according to the CABG SYNTAX score subdivided into low and high score groups by the median. A) At 10 years. B) At maximum follow-up.

Discussion

The CABG SS has been proposed for objective quantification of the residual disease and level of revascularisation in patients with previous CABG and thereby to help identify patients at higher risk of future adverse events1. The present study demonstrated that the CABG SS was possibly helpful: it identified patients with a more than threefold increase in mortality among those with prior CABG.

To improve clinical outcomes in patients with previous CABG, optimal medical therapy (OMT) is of paramount importance to mitigate disease progression in both the native coronary artery and bypass graft, given that the use of OMT was achieved infrequently in patients who underwent CABG compared to those with PCI3. The CABG SS might potentially help to identify patients in whom a more aggressive risk factor control with OMT could maximise its benefit.

Despite these secondary prevention therapies after revascularisation, patients with previous CABG sometimes undergo repeat revascularisation in the long term due to late graft failure and atherosclerotic progression of native coronary arteries. For instance, saphenous vein grafts (SVGs) have been shown to be protective in the first seven years, while, beyond that time, mortality increases significantly as SVGs lose their patency in patients who have received CABG4. In such cases, they are usually referred for PCI because of concomitant comorbidities and re-operative risks. A recent retrospective study demonstrated the prognostic value of the CABG SS in patients with prior CABG5. Additionally, an incremental prognostic benefit of the post-PCI CABG SS over the sole CABG SS in patients with previous CABG who underwent PCI was observed as attested by net reclassification improvement of 0.306 for all-cause death at five years5. These findings suggest a prognostic utility of the CABG SS in patients with previous CABG in the long term.

Limitations

In addition to the post hoc nature of the present study, the pre-specified sample size was limited in this analysis. The SYNTAX-LE MANS substudy mandated a 15-month coronary angiogram by protocol, so that the CABG SS was calculated at 15 months after the surgical procedure. In addition, the score does not take into account the type of graft anastomosed and the characteristics of the graft disease. Thus, prospective, large-scale investigations are warranted to evaluate the value of the CABG SS in the long term.

Conclusion

The present study assessed 10-year all-cause death according to the CABG SS in patients with prior CABG, showing a numerically higher risk of all-cause death in the high versus low CABG SS groups.

Impact on daily practice

The anatomical SS, as assessed before the index revascularisation, has been shown not to have any prognostic impact in patients with CABG. In contrast, the CABG SS may aid in long-term risk stratification of patients at high risk of future adverse events.

Funding

The SYNTAXES study was supported by the German Heart Research Foundation (Frankfurt am Main, Germany).

Conflict of interest statement

The authors have no conflicts of interest to declare.

Supplementary data

To read the full content of this article, please download the PDF.


References

Volume 17 Number 1
May 16, 2021
Volume 17 Number 1
View full issue


Key metrics

On the same subject

10.4244/EIJV13I7A114 Sep 20, 2017
Do the results of the SYNTAX trial apply to my centre?
Le May M et al
free

Insight

10.4244/EIJ-D-19-00543B May 20, 2020
The SYNTAX score on its way out or … towards artificial intelligence: part II
Serruys PW et al
free

10.4244/EIJV15I17A269 Apr 17, 2020
Major infections after bypass surgery and stenting: an overlooked but fatal complication
Harari R and Bangalore S
free

Editorial

10.4244/EIJ-E-22-00054 Mar 20, 2023
Periprocedural adverse events after revascularisation: the importance of getting off to a good start
Gaudino M and Dimagli A
free

Editorial

10.4244/EIJ-E-22-00008 Apr 22, 2022
SYNTAXES, biomarkers and survival in complex coronary artery disease: the intervention of secondary prevention
Gulati M and Burgess S
free

Clinical research

10.4244/EIJ-D-19-00208 Apr 17, 2020
Major infections after bypass surgery and stenting for multivessel coronary disease in the randomised SYNTAX trial
Mancone M et al
free

Editorial

10.4244/EIJ-E-23-00004 Mar 20, 2023
Revascularisation, periprocedural events and survival – and the survival of the randomised controlled trial
Lansky AJ and Ahmad Y
free
Trending articles
243.1

State of the art

10.4244/EIJ-D-21-01117 Sep 20, 2022
Recanalisation of coronary chronic total occlusions
Di Mario C et al
free
188.65

State-of-the-Art Review

10.4244/EIJ-D-21-01034 Jun 3, 2022
Management of in-stent restenosis
Alfonso F et al
free
169.3

Translational research

10.4244/EIJ-D-21-00824 May 15, 2022
Bench test and in vivo evaluation of longitudinal stent deformation during proximal optimisation
Toth GG et al
free
167.05

Expert review

10.4244/EIJ-D-21-00690 May 15, 2022
Crush techniques for percutaneous coronary intervention of bifurcation lesions
Moroni F et al
free
151.28

State-of-the-Art

10.4244/EIJ-D-22-00776 Apr 3, 2023
Computed tomographic angiography in coronary artery disease
Serruys PW et al
free
110.35

Viewpoint

10.4244/EIJ-E-22-00007 May 15, 2022
TAVI at 20: how a crazy idea led to a clinical revolution
Eltchaninoff H et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 6.2
2022 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2023)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved